Where Biogen Stands With Analysts
Portfolio Pulse from Benzinga Insights
Biogen (NASDAQ:BIIB) has received mixed analyst ratings over the past three months, with a total of 20 analysts offering their evaluations. The sentiment has shifted slightly towards a more cautious stance, with the latest 12-month price target averaging $294.95, marking a 4.71% decrease from the previous target of $309.54. Analysts from firms including JP Morgan, Barclays, and Truist Securities have adjusted their ratings and price targets, reflecting a nuanced view of Biogen's market position and financial performance. Despite facing revenue challenges and a decline in top-line earnings by -6.2%, Biogen continues to be a key player in the biotechnology sector, marketing a range of drugs for multiple sclerosis, Alzheimer's, and other conditions.

April 11, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Biogen has seen a mix of analyst ratings with a downward revision in the average price target to $294.95, reflecting a cautious outlook amidst revenue challenges and a -6.2% decline in top-line earnings.
The adjustment in analyst ratings and the decrease in the average price target suggest a more cautious outlook on Biogen's financial performance and market position. The reported revenue challenges and decline in earnings highlight underlying issues that may impact the stock's short-term performance negatively.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100